{"name":"Russian Cardiology Research and Production Center","slug":"russian-cardiology-research-and-production-center","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"atorvastatin, aspirin, losartan, amlodipine","genericName":"atorvastatin, aspirin, losartan, amlodipine","slug":"atorvastatin-aspirin-losartan-amlodipine","indication":"Secondary prevention of cardiovascular events in patients with coronary artery disease or high cardiovascular risk","status":"marketed"}]}],"pipeline":[{"name":"atorvastatin, aspirin, losartan, amlodipine","genericName":"atorvastatin, aspirin, losartan, amlodipine","slug":"atorvastatin-aspirin-losartan-amlodipine","phase":"marketed","mechanism":"This is a fixed-dose combination of four cardiovascular agents that work synergistically to reduce cholesterol, prevent thrombosis, lower blood pressure, and improve coronary blood flow.","indications":["Secondary prevention of cardiovascular events in patients with coronary artery disease or high cardiovascular risk","Hypertension management in patients requiring lipid-lowering and antiplatelet therapy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFByN2ZXZGpzSVJvRFk3d0dZc0o5dnA3LW43OWcyQUJHMDl6ejlqeTNfQ1hJb0FKNVhYTDItM21TTmFJNTYxWFFBbXRpWXp5ZHVJcnc4MlNlZkZlaVVMN3FVaA?oc=5","date":"2025-04-05","type":"pipeline","source":"ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России","summary":"Scientific life in 2019 » Almazov National Medical Research Centre - ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России","headline":"Scientific life in 2019 » Almazov National Medical Research Centre - ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBwazF1UWZQcXA3VkNSVF91THc3bkFtZXk2WFExR0dRVFJXbEdxa2JjTXBxVk5jM1NMUmlWenRwdGNPM1hmeVdFeWF3V3lkZG1oZF8tOG9R?oc=5","date":"2023-03-28","type":"pipeline","source":"Официальный сайт Мэра Москвы","summary":"Sergei Sobyanin inaugurates MEP Research & Laboratory Center / News / Moscow City Web Site - Официальный сайт Мэра Москвы","headline":"Sergei Sobyanin inaugurates MEP Research & Laboratory Center / News / Moscow City Web Site - Официальный сайт Мэра Москв","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5XVzBxVUdtS0dYREJodjJDQllHYUF0MnVpeFNPbGgtczcyN0t2XzlxbGR2ZVRMYzhhYktiSTh1cHh5SmRzdU1YdWduVjIwcXM2M3d6b3hyY2tSOXJqMEZJ?oc=5","date":"2022-10-28","type":"pipeline","source":"nature.com","summary":"Serum biomarkers, including nitric oxide metabolites (NOx), for prognosis of cardiovascular death and acute myocardial infarction in an ESSE-RF case–control cohort with 6.5-year follow up - nature.com","headline":"Serum biomarkers, including nitric oxide metabolites (NOx), for prognosis of cardiovascular death and acute myocardial i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBYWTVUYnhFdDdYcG1ERUhieC1aam9KcE50dk03N1JZblg5YndubllheEgtWGdTRXpCMGF1V3o4OXktQ3d0MXZPaUdjXzNHekRYcm5nY2psTFBMZ3RZVlAzS09HNzFPMUh6NHNacDhqcHRMLUp4?oc=5","date":"2022-03-16","type":"pipeline","source":"MedPage Today","summary":"Opinion | Why Have Pharmaceutical Giants Continued Their Operations in Russia? - MedPage Today","headline":"Opinion | Why Have Pharmaceutical Giants Continued Their Operations in Russia?","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}